Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide in High-Risk Smoldering Multiple Myeloma
NCT04370483Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Oct 2020
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of leflunomide in smoldering multiple myeloma (SMM), sponsored by City of Hope. Primary endpoint: Progressive disease up to 48 months. Started Oct 2020; status: active, not recruiting.
02
Drugs
leflunomide
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT04370483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04370483.